Imeik Technology Development Co.,Ltd.
300896
Kedudukan dalam Saham
#3859
Imeik Technology Development Co.,Ltd. specializes in the research, development,... Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.
Harga Saham
$14.06
Modal Pasaran
$4.25B
Perubahan (1 hari)
-1.89%
Perubahan (1 tahun)
-40.33%
Negara
CN
Perdagangan Imeik Technology Development Co.,Ltd. (300896)
Kategori
Healthcare
Nisbah P/B bagi Imeik Technology Development Co.,Ltd. (300896)
Nisbah P/B pada October 2026 TTM: 3.60
Menurut laporan kewangan dan harga saham terkini Imeik Technology Development Co.,Ltd., nisbah P/B semasa (TTM) ialah 3.60. Pada akhir 2023, nisbah P/B syarikat ialah 9.74.
Sejarah nisbah P/B untuk Imeik Technology Development Co.,Ltd. dari 2014 hingga 2026
Nisbah P/B pada akhir setiap tahun
| Tahun | Nisbah P/B | Ubah |
|---|---|---|
| 2026 (TTM) | 3.60 | -48.89% |
| 2024 | 7.05 | -27.60% |
| 2023 | 9.74 | -34.97% |
| 2022 | 14.97 | -9.12% |
| 2021 | 16.47 | 32.81% |
| 2020 | 12.40 | -72.01% |
| 2019 | 44.31 | -18.96% |
| 2018 | 54.68 | -18.99% |
| 2017 | 67.50 | -15.17% |
| 2016 | 79.56 | -42.30% |
| 2015 | 137.90 | -41.94% |
| 2014 | 237.50 | 0.00% |
Nisbah P/B untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/B | Perbezaan Nisbah P/B | Negara |
|---|---|---|---|
| 8.1997 | 127.55% |
US
|
|
| 1.7417 | -51.67% |
FR
|
|
| - | - |
JP
|
|
| 2.1258 | -41.01% |
US
|
|
| - | - |
CH
|
